Skip to ContentSkip to Navigation
About us Practical matters How to find us prof. dr. T. van Meerten

Publications

Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma

Facts and hopes for PET imaging-derived immunotherapy biomarkers

High frequency of severe hyperglycemia observed during intensive hematological care: a prospective study using continuous glucose monitoring

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids

Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma

R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: A propensity matched population-based study

VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses

Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities

Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study

Press/media

Dr van Meerten on the Role of Brexu-Cel in High-Risk MCL

Prof. Tom van Meerten (UMCG) over beta-hydroxybutyraat en CAR T-cel fitness

Subsidie voor onderzoek CAR-T-cellen voor mensen met multipel myeloom

Onderzoek naar effect CAR T-cellen bij terugkerende beenmergkanker krijgt subsidie

Gronings UMC gaat met overheidssubsidie zelf een prijzig buitenlands kankermedicijn maken

16,5 miljoen subsidie voor onderzoek CAR T-cellen bij beenmergkanker

Wat is de potentie van CAR-Tceltherapie bij terugkerende beenmergkanker?

UMCG krijgt miljoenen voor nieuwe behandeling van beenmergkanker: 'Je wint tijd'

Dr van Meerten on the Efficacy and Safety of Brexu-Cel in BTK Inhibitor–Naive R/R MCL

Brexu-Cel Yields High Response Rates in Relapsed/Refractory, BTK-Naive MCL